The Classic Egg-Yolk Macular Dystrophy of Childhood
Watch a fried egg through its stages — a smooth, intact yolk at first, then something closer to scrambled once it's disturbed, and finally a settled, uniform finish. Best disease follows a strikingly similar visual arc beneath the macula: a rounded, yellow deposit that starts out smooth and whole, gradually breaks apart over years, and eventually settles into its final form. That name, vitelliform, comes directly from the Latin word for egg yolk, and it is this staged journey, more than any single symptom, that shapes how the condition is followed over time.
One detail regularly surprises Somali families at a first consultation: a child can carry a strikingly visible yolk-shaped lesion on examination and still read comfortably at their expected level. The lesion's appearance and the person's actual vision simply don't always move in step, which is exactly why correctly staging the disease matters far more than reacting to how dramatic the retinal photograph looks.
During the earliest, intact stage, central vision is often only mildly affected — sometimes not affected at all — even though the lesion itself is unmistakable on examination. Symptoms tend to surface once the once-smooth deposit begins breaking apart, a stage often likened to a scrambled egg; this is typically when blurred or distorted central vision, along with difficulty with fine print, first becomes noticeable. In later, more settled stages, central vision loss becomes more firmly established, and in a smaller number of cases, abnormal blood vessel growth beneath the retina can trigger a further, sudden drop.
A faulty BEST1 gene sits at the root of this condition, ordinarily responsible for a protein called bestrophin-1 that keeps ion and fluid movement across the retinal pigment epithelium properly regulated. Once that regulation falters, fluid and pigment gather in the wrong place beneath the macula and slowly take the shape of the lesion we see on examination. It's passed down as a dominant trait, yet how strongly it shows up differs a great deal — some carriers barely notice anything despite a visible lesion, while others in the same household face more meaningful vision changes.
An electro-oculogram is the test that really settles things here, since it comes back sharply abnormal — a low Arden ratio — even in an eye whose plain ERG trace looks unremarkable, and that particular gap between the two results is what a specialist relies on to separate Best disease from lesions that merely resemble it. Repeat OCT scans, taken across successive visits rather than once, chart how the deposit is moving through its stages, and a positive BEST1 result on genetic testing not only confirms the diagnosis but also identifies which relatives might be quietly carrying the gene.
Given how long this lesion can sit without meaningful change, our early approach leans toward watching it carefully at set intervals rather than stepping in right away, keeping a particular eye out for the modest risk of abnormal vessel growth as the lesion continues its slow evolution. Once a patient's vision has genuinely begun to suffer, regenerative stem cell therapy becomes a real part of the conversation, aimed at holding onto whatever central vision is still functioning.
Yes, and it's actually one of the more reassuring things we see in the early stage of Best disease. A lesion's size on imaging doesn't translate directly into how well a person sees, which is exactly why we lean on proper staging rather than how striking the picture looks.
No — it stays entirely local to the retina and carries no connection to cancer at all. What it does do is pass through a handful of recognised stages over time, and following that progression is the whole reason we keep monitoring it.
That comes down to variable expressivity, something BEST1 mutations are well known for. She could easily carry the very same faulty gene and simply never develop a visible lesion or symptoms — the only way to know for sure is to have her tested rather than assume she's escaped it.
Not everyone — plenty of patients keep reasonably strong central vision for decades, particularly if their lesion never moves past the earlier stages. Since that course genuinely varies from person to person, ongoing monitoring is what lets us respond quickly the moment something does shift.